Monkeypox Clinical Trial
— STOMPOfficial title:
A Randomized, Placebo-Controlled, Double-Blinded Trial of the Safety and Efficacy of Tecovirimat for the Treatment of Human Monkeypox Virus Disease
A5418 is a randomized, placebo-controlled, double-blind study to establish the efficacy of tecovirimat for the treatment of people with laboratory-confirmed or presumptive HMPXV disease.
Status | Recruiting |
Enrollment | 530 |
Est. completion date | September 30, 2025 |
Est. primary completion date | May 30, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria (All participants; Arms A, B, and C): 1. Laboratory-confirmed or presumptive HMPXV infection. 2. HMPXV illness of <14 days duration immediately prior to study entry. 3. At least one active (not yet scabbed) skin lesion, mouth lesion, or proctitis with or without visible ulcers. 4. Non-pregnant people of reproductive potential must agree to use at least one effective means of contraception when engaging in sexual activities that can result in pregnancy, from the time of enrollment through the end of study participation. Additional Inclusion Criteria for Arms A and B: 1. Age =18 years at the time of study entry Additional Inclusion Criteria for Arm C; Participants who meet the above entry criteria who also meet any of the following criteria will be registered to Arm C: 1. Participants age <18 years at the time of study entry 2. Those with severe HMPXV disease Those with or without severe disease and with one or more of the following will also be enrolled into Arm C: - Severe immunosuppression - Skin conditions placing the person at higher risk for disseminated infection Exclusion Criteria (All participants; Arms A, B, and C): 1. Prior or concomitant receipt of tecovirimat (e.g., under an alternative access mechanism. 2. Planned initiation of intramuscular cabotegravir/rilpivirine during study drug administration or for two weeks following completion of study drug administration. Participants who are stable on long-acting intramuscular cabotegravir/rilpivirine may enroll. 3. Participants who, in the judgement of the investigator, will be at significantly increased risk as a result of participation in the study. 4. Participants who require intravenous dosing of tecovirimat. |
Country | Name | City | State |
---|---|---|---|
Argentina | Fundacion Huesped CRS | Buenos Aires | |
Brazil | Hospital Nossa Senhora da Conceicao CRS | Porto Alegre | |
Brazil | Centro de Pesquisas Clínicas IC-HCFMUSP CRS | São Paulo | |
Brazil | Centro de Referencia e Treinamento DST/AIDS CRS | São Paulo | |
Japan | National Center for Global Health and Medicine | Tokyo | |
Mexico | Nutricion Mexico CRS | Mexico City | |
Peru | Centro de Investigaciones Tecnológicas, Biomédicas y Medioambientales CRS (CITBM) - Unidad de Ensayos Clínicos (UNIDEC) CRS | Callao | |
Peru | Barranco CRS | Lima | |
Peru | San Miguel CRS | Lima | |
Peru | Socios En Salud Sucursal Peru | Lima | |
Peru | Via Libre CRS | Lima | |
Puerto Rico | IMPAACT/ Gamma Project/ UPR Pediatric HIV/AIDS Research CRS | San Juan | |
Puerto Rico | Puerto Rico AIDS Clinical Trials Unit CRS | San Juan | |
South Africa | Soweto CRS | Johannesburg | |
South Africa | University of the Witwatersrand Helen Joseph (WITS HJH) | Johannesburg | |
Thailand | Mahidol University CRS | Bangkok | |
Thailand | Thai Red Cross AIDS Research Centre | Bangkok | |
United States | The Ponce de Leon Center CRS | Atlanta | Georgia |
United States | University of Colorado Denver NICHD CRS | Aurora | Colorado |
United States | University of Colorado Hospital CRS | Aurora | Colorado |
United States | Johns Hopkins University CRS | Baltimore | Maryland |
United States | Alabama CRS | Birmingham | Alabama |
United States | Brigham and Women's Hospital Therapeutics | Boston | Massachusetts |
United States | Massachusetts General Hospital CRS (MGH CRS) | Boston | Massachusetts |
United States | Jacobi Medical Center Bronx NICHD CRS | Bronx | New York |
United States | Ann & Robert H Lurie Children's Hospital of Chicago | Chicago | Illinois |
United States | Northwestern University | Chicago | Illinois |
United States | Rush University Cook County Hospital Chicago NICHD CRS | Chicago | Illinois |
United States | Rush University CRS | Chicago | Illinois |
United States | Cincinnati CRS | Cincinnati | Ohio |
United States | Case Western Reserve University CTU | Cleveland | Ohio |
United States | Ohio State University CRS | Columbus | Ohio |
United States | North Texas Infectious Disease Consultants | Dallas | Texas |
United States | Trinity Health and Wellness Center CRS | Dallas | Texas |
United States | UT Southwestern Infectious Disease Research Unit | Dallas | Texas |
United States | Denver Public Health CRS | Denver | Colorado |
United States | Henry Ford Hospital CRS | Detroit | Michigan |
United States | Duke University Medical Center CRS | Durham | North Carolina |
United States | University of Florida | Gainesville | Florida |
United States | Baylor College of Medicine / Texas Children's Hospital NICHD CRS | Houston | Texas |
United States | Houston AIDS Research Team (HART) CRS | Houston | Texas |
United States | University of Florida Jacksonville NICHD CRS | Jacksonville | Florida |
United States | David Geffen School of Medicine at UCLA NICHD CRS | Los Angeles | California |
United States | Kaiser Permanente Los Angeles Medical Center | Los Angeles | California |
United States | Los Angeles LGBT Center CRS | Los Angeles | California |
United States | UCLA CARE Center CRS | Los Angeles | California |
United States | Usc La Nichd Crs | Los Angeles | California |
United States | St. Jude Children's Research Hospital ATN CRS | Memphis | Tennessee |
United States | University of Miami / Jackson Memorial Hospital | Miami | Florida |
United States | University of Miami/Pediatric Perinatal HIV NICHD CRS | Miami | Florida |
United States | Vanderbilt Therapeutics CRS | Nashville | Tennessee |
United States | Yale University School of Medicine | New Haven | Connecticut |
United States | Bronx-Lebanon Hospital Center NICHD CRS | New York | New York |
United States | Columbia Physicians & Surgeons (P&S) CRS | New York | New York |
United States | Harlem Prevention Center | New York | New York |
United States | Infectious Disease Clinical and Translational Research | New York | New York |
United States | Mount Sinai West Samuels CRS | New York | New York |
United States | Weill Cornell Chelsea CRS | New York | New York |
United States | Weill Cornell Uptown CRS | New York | New York |
United States | New Jersey Medical School Clinical Research Center | Newark | New Jersey |
United States | Easy Bay AIDS Center CRS City: Oakland | Oakland | California |
United States | University of Nebraska Medical Center (Specialty Care Center) | Omaha | Nebraska |
United States | Penn Therapeutics CRS | Philadelphia | Pennsylvania |
United States | University of Pittsburgh CRS | Pittsburgh | Pennsylvania |
United States | Virginia Commonwealth University Division of Infectious Diseases | Richmond | Virginia |
United States | University of Rochester Adult HIV Therapeutic | Rochester | New York |
United States | University of California, Davis CRS | Sacramento | California |
United States | Washington University Therapeutics (WT) CRS | Saint Louis | Missouri |
United States | University of Texas, San Antonio | San Antonio | Texas |
United States | UCSD Antiviral Research Center CRS | San Diego | California |
United States | University of California, San Francisco HIV/AIDS CRS | San Francisco | California |
United States | University of Washington Positive Research | Seattle | Washington |
United States | SUNY Stony Brook NICHD CRS | Stony Brook | New York |
United States | Univ. of South Florida (USF) College of Medicine A | Tampa | Florida |
United States | Harbor University of California Los Angeles Center | Torrance | California |
United States | Wake Forest Baptist Medical Center CRS | Winston-Salem | North Carolina |
Lead Sponsor | Collaborator |
---|---|
National Institute of Allergy and Infectious Diseases (NIAID) | SIGA Technologies |
United States, Argentina, Brazil, Japan, Mexico, Peru, Puerto Rico, South Africa, Thailand,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Time to clinical resolution, defined as the first day on which all skin lesions are scabbed, desquamated or healed, and visible mucosal lesions are healed | Up to day 29 | ||
Secondary | Pain assessed by 11-point numerical rating scale for pain | Through day 29 | ||
Secondary | Time to development of severe HMPXV in those without severe HMPXV at baseline | Through day 57 | ||
Secondary | Level of HMPXV in blood | Through day 57 | ||
Secondary | Level of HMPXV in skin lesions | Through day 57 | ||
Secondary | Level of HMPXV in oropharynx | Through day 57 | ||
Secondary | Level of HMPXV in rectum | Through day 57 | ||
Secondary | Level of HMPXV in genital secretions | Through day 57 | ||
Secondary | Time to complete lesion healing defined as all lesions being re-epithelialized | Up to day 29 | ||
Secondary | Participant-reported adherence | Through day 15 | ||
Secondary | Participant-reported quality-of-life as measured by EQ-5D-5L | Through day 29 | ||
Secondary | Occurrence of Grade 3 or greater adverse event | Through day 57 | ||
Secondary | All-cause mortality | Through day 57 | ||
Secondary | Tecovirimat concentrations in blood in children less than 18 years of age | Through day 15 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05512949 -
Trial to Evaluate the Immunogenicity of Dose Reduction Strategies of the MVA-BN Monkeypox Vaccine
|
Phase 2 | |
Completed |
NCT05976100 -
Study of the Safety, Tolerability, Pharmacokinetics of NIOCH-14 in Volunteers Aged 18-50 Years
|
Phase 1 | |
Recruiting |
NCT05988203 -
A Clinical Study Investigating the Safety and Immune Responses After Immunization With Investigational Monkeypox Vaccines
|
Phase 1 | |
Terminated |
NCT05567939 -
Clinical, Virological, Immunological, Psychosocial and Epidemiological Consequences of Human Monkeypox Virus (ProMPX)
|
||
Active, not recruiting |
NCT05562323 -
Characterization of Vaccine-induced Responses Against Monkeypox (MoVIHvax) An Observational Prospective Cohort Study
|
||
Not yet recruiting |
NCT05784038 -
Observational, Prospective, Cohort Study of Mpox Infection in Brazil (NETPOX)
|
||
Not yet recruiting |
NCT05745987 -
Smallpox Vaccine for Mpox Post-Exposure Prophylaxis: A Cluster RCT
|
Phase 4 | |
Recruiting |
NCT05879965 -
Prospective Study for the FOLLOW-UP of Human Monkeypox Cases and Smallpox Vaccinees at Risk
|
||
Completed |
NCT03745131 -
Cohort Study of Healthcare Workers Receiving Imvanex®
|
||
Recruiting |
NCT05559099 -
Tecovirimat for Treatment of Monkeypox Virus
|
Phase 2 | |
Completed |
NCT05846243 -
Study on Immunogenicity, Reactogenicity and Safety of the VACΔ6 Vaccine in Volunteers Aged 18-60 Years
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT05629299 -
Pilot Study to Detect Monkey Pox Virus in Sperm: POXSPERM
|
N/A | |
Recruiting |
NCT05654883 -
New York City Observational Study of Mpox Immunity
|
||
Completed |
NCT05762523 -
Safety and Tolerability Study of the VAC∆6 Vaccine in Volunteers Aged 18-40 Years
|
Phase 1 | |
Recruiting |
NCT05597735 -
Assessment of the Efficacy and Safety of Tecovirimat in Patients With Monkeypox Virus Disease
|
Phase 3 | |
Recruiting |
NCT05734508 -
Assessment of Safety Profile of MVA-BN Vaccine in the PALM-007 Study in DRC
|
Phase 4 | |
Active, not recruiting |
NCT05740982 -
A Phase 2 Randomized Multisite Trial to Inform Public Health Strategies Involving the Use of MVA-BN Vaccine for Mpox
|
Phase 2 | |
Recruiting |
NCT06045923 -
Virologic and Immunologic Characteristics of Severe Mpox in Persons With Advanced HIV
|
||
Recruiting |
NCT05947786 -
Mpox Paediatric and Adolescent Clinical Study
|
||
Completed |
NCT05476744 -
Viral Clearance and Epidemiological Characteristics in Patients With Monkeypox
|